Study guide

6.2 Pediatric Epilepsy Syndromes in the EMU

ABRET Certified Long Term Monitoring Technologist CLTM

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pre-Study Preparation & Clinical Indications

1.1 Clinical Indications for Long-Term Monitoring 1.2 Patient History, Clinical Assessment & Neurological Evaluation 1.3 Recording Strategy, Protocol Planning & Patient Communication

2 Chapter 2: Electrodes, Montages & Technical Setup

2.1 Electrode Selection, Application & Scalp Integrity 2.2 True and Modified Montages for LTM 2.3 Instrument Settings, Calibration & Differential Amplification 2.4 Signal Integrity, Impedance Monitoring & Artifact Troubleshooting

3 Chapter 3: Seizure Classification, Semiology & Clinical Events

3.1 ILAE 2017 Seizure Classification Framework 3.2 Seizure Semiology & Ictal Phenotypes 3.3 Differentiating Epileptic vs Non-Epileptic Events 3.4 Event Button Workflow, Clinical Testing & Ictal Observation

4 Chapter 4: EEG Waveform Identification & Interictal Discharges

4.1 Normal Variants and Benign Epileptiform Patterns 4.2 Interictal Epileptiform Discharges (IEDs) 4.3 Electrographic and Electroclinical Seizure Patterns

5 Chapter 5: ICU Continuous EEG & Critical Care Monitoring

5.1 ACNS Standardized Critical Care Terminology 5.2 Non-Convulsive Status Epilepticus (NCSE) & Salzburg Criteria 5.3 Coma Patterns, Burst Suppression & Prognostication 5.4 Quantitative EEG (qEEG) Trends & ICU Trending Tools

6 Chapter 6: Age-Specific Monitoring: Neonatal & Pediatric LTM

6.1 Neonatal EEG & Continuous Monitoring 6.2 Pediatric Epilepsy Syndromes in the EMU 6.3 Pediatric Technical Considerations & Behavioral Strategies

7 Chapter 7: Invasive Intracranial Monitoring & Functional Mapping

7.1 Intracranial Recording Modalities (Grids, Strips, SEEG) 7.2 Extraoperative Functional Brain Mapping & Cortical Stimulation 7.3 Somatosensory Evoked Potentials (SEPs) & Central Sulcus Localization

8 Chapter 8: Provocative Testing & In-Study Interventions

8.1 Activation Procedures in LTM (HV, Photic, Sleep Deprivation) 8.2 Medication Withdrawal & Provocation Protocols 8.3 Emergency Escalation & Status Epilepticus Management

9 Chapter 9: Post-Study Procedures, Technical Reporting & Localization

9.1 Technical Summary & Technologist Reporting 9.2 Data Review, Reformatting & Montage Re-montaging 9.3 Localization Techniques & Dipole Principles 9.4 Study Completion, Electrode Removal & Infection Prevention

10 Chapter 10: Data & Equipment Management

10.1 Video-EEG Synchronization & Audio-Visual Systems 10.2 Data Pruning, Clipping & Archiving 10.3 Network Infrastructure, Server Systems & Hardware Maintenance

11 Chapter 11: Ethics, Patient Safety & Professional Standards

11.1 Patient Safety Protocols & Fall Prevention in the EMU 11.2 Regulatory Compliance: HIPAA, HITECH & Video Privacy 11.3 CPT and ICD-10 Coding for LTM Services 11.4 ABRET Code of Ethics & Professional Practice Standards

6.2 Pediatric Epilepsy Syndromes in the EMU

Key Takeaways Explain This Topic AI

Self-Limited Epilepsy with Centrotemporal Spikes (SeLECTS / Rolandic Epilepsy) features nocturnal sensorimotor focal seizures with speech arrest and preserved awareness, demonstrating high-amplitude centrotemporal spikes with a characteristic tangential (horizontal) dipole (centrotemporal negativity with anterior frontal positivity).

West Syndrome (Infantile Spasms) is defined by the clinical triad of epileptic spasms in clusters upon waking, hypsarrhythmia (chaotic, >200–300 µV background with multifocal spikes), and developmental regression, treated first-line with ACTH/corticosteroids or Vigabatrin (first-line for Tuberous Sclerosis Complex).

Lennox-Gastaut Syndrome (LGS) is characterized by multiple intractable seizure types (nocturnal tonic seizures, atonic drop attacks, atypical absence), slow spike-and-wave (<2.5 Hz) during wakefulness, and Generalized Paroxysmal Fast Activity (GPFA, 10–20 Hz) in NREM sleep; corpus callosotomy is the surgical procedure of choice for drop attacks.

Dravet Syndrome is caused by loss-of-function SCN1A mutations impairing Nav1.1 sodium channels on GABAergic inhibitory interneurons; sodium channel blocking ASMs (carbamazepine, phenytoin, lamotrigine) are strictly contraindicated because they precipitate refractory status epilepticus.

Childhood Absence Epilepsy (CAE) is characterized by brief staring spells with abrupt onset and offset, immediate cognitive recovery, and generalized, synchronous, symmetric frontally dominant 3 Hz spike-and-wave discharges activated by 3-minute hyperventilation, treated first-line with Ethosuximide.

Last updated: August 2026

6.2 Pediatric Epilepsy Syndromes in the EMU

Long-term video-EEG monitoring in the pediatric Epilepsy Monitoring Unit (EMU) plays an indispensable role in diagnosing developmental and epileptic encephalopathies (DEEs), characterizing paroxysmal spells, evaluating surgical candidacy, and guiding precision pharmacotherapy. In pediatric neurology, an electroclinical syndrome is defined by a specific constellation of clinical features, age of onset, seizure semiologies, neuroimaging findings, genetic etiologies, and distinct interictal and ictal electrographic patterns.

Misclassifying a pediatric epilepsy syndrome can have severe clinical consequences—ranging from administering contraindicated medications that provoke refractory status epilepticus (such as sodium channel blockers in Dravet syndrome) to missing the critical therapeutic window for neurodevelopmental preservation (such as delayed hormonal therapy in Infantile Spasms).

1. Self-Limited Epilepsy with Centrotemporal Spikes (SeLECTS / Rolandic Epilepsy)

Self-Limited Epilepsy with Centrotemporal Spikes (formerly designated Benign Rolandic Epilepsy or Benign Epilepsy with Centrotemporal Spikes / BECTS) is the most common focal epilepsy syndrome of childhood, accounting for 15% to 25% of pediatric epilepsies. Onset occurs between 3 and 12 years of age (peak 7 to 9 years), with an excellent prognosis and spontaneous remission by mid-adolescence (14 to 16 years). +-----------------------------------------------------------------------------+

  • | SeLECTS / BENIGN ROLANDIC EPILEPSY PROFILE |
  • | |
  • | [1] CLINICAL SEMIOLOGY |
  • | - Nocturnal / Sleep-Related Onset: > 75% of seizures occur during |
  • | drowsiness, sleep, or upon awakening. |
  • | - Sensorimotor Rolandic Features: Unilateral facial twitching, clonic |
  • | mouth pulling, perioral paresthesias/numbness (tongue, cheek, gums).|
  • | - Anarthria & Salivation: Inability to speak (speech arrest) with |
  • | guttural vocalizations and prominent drooling/hypersalivation. |
  • | - Preserved Awareness: Consciousness remains completely INTACT in |
  • | focal seizures; may evolve into focal to bilateral tonic-clonic. |
  • | |
  • | [2] EEG HALLMARK: THE TANGENTIAL (HORIZONTAL) DIPOLE |
  • | - Broad, high-voltage (100 to 300+ uV) diphasic/triphasic sharp waves |
  • | with a prominent following slow wave at C3/T3 or C4/T4. |
  • | - Tangential Dipole: Maximum negative pole over centrotemporal leads |
  • | (C3/C4, T3/T4) with simultaneous maximum positive pole over the |
  • | anterior frontal leads (Fp1/Fp2). |
  • | - Sleep Activation: Markedly increased firing rate (frequent clusters |
  • | and runs) during NREM sleep stages N2 and N3. |
  • | - Normal Background: Awake background and posterior dominant rhythm |
  • | remain completely normal for age. |

+-----------------------------------------------------------------------------+ +-----------------------------------------------------------------------------+

  • | SeLECTS TANGENTIAL (HORIZONTAL) DIPOLE SCHEMATIC |
  • | |
  • | ( Anterior Frontal: Fp1 / Fp2 ) --> [ + POSITIVE POLE + ] |
  • | | |
  • | | ( Tangential Current Vector ) |
  • | v |
  • | ( Centrotemporal: C3/T3, C4/T4 ) --> [ - NEGATIVE POLE - ] |
  • | |
  • | *Note: In average or referential montages, the centrotemporal leads show |
  • | high-amplitude downward/upward negative spikes while Fp1/Fp2 show an |
  • | inverted positive mirror deflection. |
  • +-----------------------------------------------------------------------------+
  • 2. West Syndrome / Infantile Spasms (Epileptic Spasms)

West Syndrome is an age-specific developmental and epileptic encephalopathy that typically manifests between 3 and 12 months of age (peak onset at 4 to 7 months). It represents a pediatric neurological emergency requiring immediate identification and aggressive therapeutic intervention. +-----------------------------------------------------------------------------+

  • | WEST SYNDROME CLASSICAL DIAGNOSTIC TRIAD |
  • | |
  • | [1] EPILEPTIC SPASMS |
  • | - Sudden, brief (0.5 to 2.0 seconds) axial contractions. |
  • | - Types: Flexor (jackknife / bowing), Extensor (arms abduct/extend), |
  • | or Mixed flexor-extensor. |
  • | - Characteristic Clustering: Occur in rapid clusters (20 to 100+ |
  • | spasms spaced 5 to 30 seconds apart), predominantly upon awakening |
  • | or during sleep-wake transitions. |
  • | |
  • | [2] HYPSARRHYTHMIA ON INTERICTAL EEG |
  • | - Chaotic, disorganized, extremely high-voltage (> 200 to 300+ uV) |
  • | background with no identifiable normal background rhythms. |
  • | - Random, multifocal sharp waves, spikes, and polyspikes shifting |
  • | continuously in location and duration across both hemispheres. |
  • | |
  • | [3] DEVELOPMENTAL ARREST OR REGRESSION |
  • | - Loss of previously acquired motor and social milestones (e.g., |
  • | loss of visual fixation, head control, social smiling). |
  • +-----------------------------------------------------------------------------+
  • Ictal Electrographic Spasm Architecture

During an epileptic spasm, synchronized video-EEG demonstrates a characteristic three-phase electrographic complex: +-----------------------------------------------------------------------------+

  • | ICTAL ELECTROGRAPHIC SPASM COMPLEX |
  • | |
  • | [Phase 1: High-Voltage Slow Wave / Polyspike] |
  • | - A prominent, generalized synchronous high-voltage (200-400 uV) slow |
  • | wave or sharp-and-slow wave complex lasting 0.5 to 1.5 seconds. |
  • | |
  • | [Phase 2: Electrodecremental Response (Electrodecrement)] |
  • | - An abrupt, profound generalized voltage attenuation / flattening of all |
  • | cortical activity (< 10-20 uV) lasting 1 to 5+ seconds. |
  • | |
  • | [Phase 3: Low-Voltage Superimposed Fast Activity (Beta / Gamma)] |
  • | - Rhythmic 14 to 30 Hz fast activity riding upon the decremental trough, |
  • | correlating directly with the clinical muscle spasm. |
  • +-----------------------------------------------------------------------------+
  • Etiologies & First-Line Pharmacotherapy

Etiological Categories: Structural (e.g., hypoxic-ischemic encephalopathy, focal cortical dysplasia, perinatal stroke), Genetic (e.g., Tuberous Sclerosis Complex [TSC1/TSC2] , Down syndrome, CDKL5 , ARX ), Metabolic, or Cryptogenic/Unknown.

First-Line Medical Therapies:

Adrenocorticotropic Hormone (ACTH) or high-dose oral corticosteroids (Prednisolone): First-line therapy for non-TSC infantile spasms, achieving rapid clinical cessation of spasms and electrographic resolution of hypsarrhythmia.

Vigabatrin (Sabril): First-line therapy of choice in patients with Tuberous Sclerosis Complex (TSC) (efficacy >80%). Vigabatrin irreversibly inhibits GABA transaminase, elevating cerebral GABA. Safety requirement: Baseline and serial ophthalmologic visual field testing due to the risk of irreversible peripheral visual field constriction (retinal toxicity).

3. Lennox-Gastaut Syndrome (LGS)

Lennox-Gastaut Syndrome is a severe epileptic encephalopathy accounting for 3% to 4% of childhood epilepsies, typically emerging between 2 and 8 years of age (peak 3 to 5 years). Approximately 20% to 30% of cases evolve directly from earlier West Syndrome. +-----------------------------------------------------------------------------+

  • | LENNOX-GASTAUT SYNDROME (LGS) TRIAD |
  • | |
  • | [1] MULTIPLE INTRACTABLE SEIZURE TYPES |
  • | - Tonic Seizures: Hallmark of LGS, predominantly nocturnal (in NREM). |
  • | - Atonic Seizures (Astatic / Drop Attacks): Sudden loss of postural |
  • | tone causing catastrophic forward/backward falls and head trauma. |
  • | - Atypical Absence: Gradual onset and offset with partial unrespons. |
  • | - Myoclonic, Focal, and Generalized Tonic-Clonic seizures. |
  • | |
  • | [2] CHARACTERISTIC INTERICTAL & ICTAL EEG PATTERNS |
  • | - Slow Spike-and-Wave Discharges: < 2.5 Hz (typically 1.5 to 2.0 Hz), |
  • | diffuse, bilateral, frontally predominant during wakefulness. |
  • | - Generalized Paroxysmal Fast Activity (GPFA): Bursts of 10 to 20 Hz |
  • | rhythmic beta activity (50 to 100+ uV) lasting 2 to 10 seconds in |
  • | NREM sleep, classically coinciding with subclinical or overt tonic |
  • | seizures. |
  • | |
  • | [3] COGNITIVE IMPAIRMENT & PSYCHOMOTOR SLOWING |
  • | - Progressive intellectual disability and prominent behavioral issues |
  • | (hyperactivity, aggression, autistic traits). |
  • +-----------------------------------------------------------------------------+
  • Management & Palliative Surgery

Medical Therapy: Highly drug-resistant. Broad-spectrum agents include Valproate , Clobazam , Rufinamide , Cannabidiol (CBD) , Lamotrigine , Topiramate , and Felbamate (requires monitoring for aplastic anemia and hepatic failure).

Palliative Surgical Options:

Corpus Callosotomy: Highly effective palliative surgical procedure (complete or anterior two-thirds callosotomy) designed to disconnect interhemispheric propagation pathways, dramatically reducing or eliminating catastrophic atonic drop attacks and preventing traumatic head injury.

Vagus Nerve Stimulation (VNS): Palliative neuromodulatory adjunctive therapy to reduce overall seizure burden.

4. Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)

Dravet syndrome is a catastrophic genetic epileptic encephalopathy with onset during the first year of life (typically 4 to 12 months) in previously healthy infants with normal baseline development. +-----------------------------------------------------------------------------+

  • | DRAVET SYNDROME PATHOPHYSIOLOGY & EVOLUTION |
  • | |
  • | [1] GENETIC UNDERPINNING |
  • | - De novo loss-of-function heterozygous mutations in the SCN1A gene |
  • | (> 80-85% of patients), encoding the Nav1.1 voltage-gated sodium |
  • | channel alpha subunit. |
  • | - Pathophysiology: Selectively impairs action potential firing in |
  • | GABAergic inhibitory interneurons, producing severe uninhibited |
  • | cortical hyperexcitability. |
  • | |
  • | [2] CLINICAL EVOLUTION |
  • | - Year 1 (Febrile Stage): Prolonged, recurrent, febrile or afebrile |
  • | hemiclonic or generalized convulsive status epilepticus, frequently |
  • | triggered by fever, illness, warm ambient baths, or vaccination. |
  • | - Years 2-5 (Catastrophic Stage): Emergence of multiple refractory |
  • | seizure types (myoclonic jerks, atypical absence, focal seizures, |
  • | non-convulsive status epilepticus / obtundation status) accompanied |
  • | by developmental stagnation, ataxia, and cognitive decline. |
  • | |
  • | [3] EEG FINDINGS |
  • | - Normal in the first year of life! Progresses to diffuse background |
  • | slowing, multifocal spikes, generalized spike-wave, and profound |
  • | photosensitivity. |
  • +-----------------------------------------------------------------------------+

Caution

CRITICAL PHARMACOLOGICAL CONTRAINDICATION IN DRAVET SYNDROME: Sodium channel blocking anti-seizure medications are strictly CONTRAINDICATED in Dravet syndrome:

Contraindicated Drugs: Carbamazepine, Oxcarbazepine, Phenytoin, Fosphenytoin, Lamotrigine, Lacosamide.

Mechanism of Harm: Because the underlying SCN1A mutation already cripples Nav1.1 sodium channels on GABAergic inhibitory interneurons, adding a sodium channel blocker further shuts down inhibitory networks, paradoxically provoking catastrophic, treatment-refractory status epilepticus and accelerating cognitive regression.

Approved / First-Line Regimens: Fenfluramine , Stiripentol , Cannabidiol (Epidiolex) , Clobazam , and Valproate ; Ketogenic diet.

5. Childhood Absence Epilepsy (CAE)

Childhood Absence Epilepsy represents the prototypical idiopathic (genetic) generalized epilepsy syndrome, accounting for 10% to 15% of all pediatric epilepsies. Onset occurs between 4 and 10 years of age (peak 5 to 7 years), with a female predominance. +-----------------------------------------------------------------------------+

  • | CHILDHOOD ABSENCE EPILEPSY (CAE) PROFILE |
  • | |
  • | [1] CLINICAL SEMIOLOGY |
  • | - Sudden, brief (4 to 20 seconds) behavioral arrest and staring. |
  • | - Complete unresponsiveness; mild automatisms (eyelid fluttering, lip |
  • | smacking) occur in 50% of spells. |
  • | - High Frequency: Tens to hundreds of episodes per day. |
  • | - No Aura and NO Post-Ictal Confusion: The child immediately resumes |
  • | pre-ictal conversation or activity without realizing a spell occurred.|
  • | |
  • | [2] EEG HALLMARK |
  • | - Baseline Background: Normal, well-organized for age with normal PDR.|
  • | - Ictal Discharge: Generalized, synchronous, symmetrical, frontally |
  • | dominant 3 Hz (2.5 to 4.0 Hz) Spike-and-Wave Discharges (GSWD). |
  • | - Discharge Characteristics: Abrupt onset and abrupt offset; voltage |
  • | typically > 200 to 300 uV with maximum amplitude at F3/F4/Fz. |
  • | |
  • | [3] PROVOCATIVE TESTING & PHARMACOTHERAPY |
  • | - Hyperventilation (HV): 3-minute standard HV provokes typical absence|
  • | seizures in > 90% of untreated patients (mandatory in EMU). |
  • | - First-Line Therapy: Ethosuximide (Zarontin) is the first-line drug |
  • | of choice (blocks thalamocortical T-type calcium channels); Valproate|
  • | is alternative first-line; Lamotrigine is second-line. |
  • +-----------------------------------------------------------------------------+
  • 6. High-Yield Pediatric Epilepsy Syndromes Comparison Matrix

Syndrome Typical Age of Onset Hallmark Clinical Semiology Interictal EEG Features Ictal EEG Signature First-Line Management

SeSELECTS (Rolandic) 3–12 years Nocturnal hemifacial twitching, perioral numbness, speech arrest, preserved awareness Centrotemporal sharp waves with tangential dipole; NREM sleep activation Evolving centrotemporal rhythmic sharp-and-slow wave activity Observation / Levetiracetam / Sulthiame (often resolves spontaneously)

West Syndrome 3–12 months Clusters of flexor/extensor axial epileptic spasms upon waking Hypsarrhythmia (chaotic, >200 µV, multifocal spikes) High-voltage slow wave followed by electrodecrement + fast beta ACTH / Corticosteroids; Vigabatrin (for TSC)

Lennox-Gastaut (LGS) 2–8 years Intractable tonic seizures in sleep, atonic drop attacks, atypical absence Slow spike-wave (<2.5 Hz); Generalized Paroxysmal Fast Activity (GPFA) in NREM GPFA (10–20 Hz) with tonic seizures; slow spike-wave with absence Valproate, Clobazam, Rufinamide, CBD; Corpus Callosotomy

Dravet Syndrome 4–12 months Prolonged febrile/afebrile hemiclonic status; evolves to myoclonic/focal spells Normal in year 1; progresses to multifocal spikes and photosensitivity Variable focal, hemiclonic, or generalized discharges Fenfluramine, Stiripentol, CBD, Clobazam ( NO Na+ blockers! )

Childhood Absence (CAE) 4–10 years Brief (4–20s) staring spells, abrupt onset/offset, immediate recovery, no aura Normal background; responsive to hyperventilation activation Generalized synchronous symmetric frontally dominant 3 Hz spike-and-wave Ethosuximide (1st line), Valproate, Lamotrigine